The Court of Appeal has overturned the High Court’s finding of non-infringement, holding Napp’s divisional patents, relating to controlled release formulations of a painkiller called oxycodone, to be valid and infringed by Ratiopharm’s and Sandoz’s ‘Cimex’ product. The Court of Appeal’s finding of infringement contrasts with decisions in Germany where the German designation of the patents were found to be not infringed.
The full summary of this case has been published on Kluwer IP Law.
To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.
Kluwer IP Law
The 2022 Future Ready Lawyer survey showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?
Learn how Kluwer IP Law can support you.